

Please rewrite Claims 3, 7 and 8 as follows:

1 3. Use according to claim 1, wherein said disorder is a
2 peripheral and/or CNS-disorder.

1 7. The pharmaceutical composition according to claim 5,
2 wherein said compound is an antibody directed to TGF- β or a
3 compound having the binding site of a TGF- β receptor.

8. The pharmaceutical composition according to claim 5,
wherein said second compound is selected from the group
consisting of urokinase and tissue plasminogen activator.

A marked-up version of the above showing additions and
deletions is attached for the Examiner's convenience.

Please add new claims 9 through 13 below.

1 9. Use according to claim 2, wherein said disorder is a
2 peripheral and/or CNS-disorder.

1 10. Use according to claim 9, wherein said disorder is a
2 cerebral ischemia or a neurodegenerative disorder.

11. The pharmaceutical composition according to claim 6,
wherein said compound is an antibody directed to TGF- β or a
compound having the binding site of a TGF- β receptor.

12. The pharmaceutical composition according to claim 6,
wherein said second compound is selected from the group
consisting of urokinase and tissue plasminogen activator.

13. The pharmaceutical composition according to claim 12,
wherein said second compound is selected from the group
consisting of urokinase and tissue plasminogen activator.

REMARKS

This Preliminary Amendment puts the claims into proper form
for examination. Kindly calculate the filing fee based on the
amended claims.